文献速递临床微生物质量管理与危急值

伯克霍尔德菌复合群流行病学折点建立的挑战

Challenges in establishing epidemiological cut-off values for the Burkholderia cepacia complex.
PubMed 文献 · J Clin Microbiol · 2026-09-25

伯克霍尔德菌复合群(BCC)包含24种革兰阴性菌,CLSI已移除其纸片扩散和MIC折点。本研究基于3项既往研究和3个独立实验室的1896株BCC分离株MIC数据,计算了头孢他啶、左氧氟沙星、美罗培南、米诺环素和复方磺胺甲噁唑的流行病学折点(ECV)。头孢他啶、左氧氟沙星、美罗培南和米诺环素的ECV分别为16、8、16和8 μg/mL,而复方磺胺甲噁唑的ECV因分析不同为2、8或16 μg/mL,无法可靠建立。建立ECV面临合并MIC数据集局限、MIC分布宽泛及ECV高于过时敏感折点等挑战,限制了其临床实用性,支持从CLSI M100标准中移除ECV。

要点

  • BCC的ECV:头孢他啶16 μg/mL,左氧氟沙星8 μg/mL,美罗培南16 μg/mL,米诺环素8 μg/mL。
  • 复方磺胺甲噁唑ECV因分析不同为2、8或16 μg/mL,无法可靠建立。
  • ECV建立挑战包括数据局限、MIC分布宽泛及ECV高于过时敏感折点,限制临床实用性。

核心结论

  • BCC中头孢他啶、左氧氟沙星、美罗培南和米诺环素的ECV可建立,但复方磺胺甲噁唑的ECV无法可靠建立。
  • 建立ECV的挑战限制其临床实用性,支持从CLSI M100标准中移除ECV。

研究设计与样本

  • 基于3项既往研究和3个独立实验室的MIC数据,共纳入1896株BCC分离株进行ECV分析。

主要发现

  • 头孢他啶ECV为16 μg/mL,左氧氟沙星ECV为8 μg/mL,美罗培南ECV为16 μg/mL,米诺环素ECV为8 μg/mL。
  • 复方磺胺甲噁唑ECV因分析不同分别为2、8和16 μg/mL,无法可靠建立。

关键数值与推荐

  • 头孢他啶ECV 16 μg/mL,左氧氟沙星ECV 8 μg/mL,美罗培南ECV 16 μg/mL,米诺环素ECV 8 μg/mL。
  • 复方磺胺甲噁唑ECV为2、8或16 μg/mL(依分析而异),无法可靠建立。

临床怎么用

  • 在缺乏折点的情况下,ECV可用于判断BCC分离株为野生型或非野生型表型。
  • 由于ECV建立存在挑战且部分ECV高于过时敏感折点,其临床指导治疗的价值有限。

局限性

  • 合并MIC数据集存在局限性。
  • BCC的MIC分布宽泛。
  • 部分ECV高于过时的敏感MIC折点,限制临床实用性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: The Burkholderia cepacia complex (BCC) is comprised of 24 species of gram-negative bacteria that cause opportunistic infections. While antimicrobial susceptibility testing (AST) has historically been used to guide treatment for BCC infections, recent work highlighting problems with AST for these organisms led the Clinical and Laboratory Standards Institute (CLSI) to remove disk diffusion and minimal inhibitory concentration (MIC) breakpoints for BCC from its M100 standards document. Epidemiological cut-off values (ECVs) may be helpful to clinicians in the absence of breakpoints, as they may be used to determine whether an isolate has a wild-type or non-wild-type phenotype. Here, we present an analysis of BCC ECVs for ceftazidime (CAZ), levofloxacin (LVX), meropenem (MEM), minocycline (MIN), and trimethoprim-sulfamethoxazole (TMP-SMX). ECVs were calculated using MIC data from 3 previous studies and 3 independent laboratories for 1,896 BCC isolates. ECVs were 16 μg/mL for CAZ, 8 μg/mL for LVX, 16 μg/mL for MEM, and 8 μg/mL for MIN. The ECV for TMP-SMX varied depending on the analysis from 2, 8, and 16 μg/mL and therefore could not be reliably established. Challenges with establishing ECVs for BCC include limitations with the pooled MIC data set, broad MIC distributions, and high ECVs that are above the obsolete susceptible MIC breakpoints. These challenges limit the clinical utility of ECVs for these organisms and support the removal of ECVs from the CLSI M100 standards document. IMPORTANCE: The Burkholderia cepacia complex is a group of bacterial species that cause difficult-to-treat opportunistic infections. Recently, clinical breakpoints, which are used to determine whether organisms are susceptible to certain antimicrobials, were removed from Clinical and Laboratory Standards Institute (CLSI) standards for these organisms due to problems with antimicrobial susceptibility testing performance. Clinicians are now faced with the challenge of how to treat these complex infections without clinical breakpoints. Here, we determine epidemiological cut-off values (ECVs) for relevant antimicrobials for the B. cepacia complex. While we established ECVs for ceftazidime, levofloxacin, meropenem, and minocycline, we were unable to determine a reliable ECV for trimethoprim-sulfamethoxazole. Additionally, we encountered significant challenges in our analyses, including data limitations for these organisms and high ECVs that are not clinically useful. These challenges limit the practical use of these ECVs in helping guide treatment and support the removal of ECVs from the CLSI M100 standards document.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Huse HK, Manuel C, McLemore T, et al. Challenges in establishing epidemiological cut-off values for the Burkholderia cepacia complex. J Clin Microbiol. 2026. PMID: 42788749. doi:10.1128/jcm.00730-26

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。